Effect of B.Lactis Consumption on Gastro-Intestinal (GI) Symptoms in Healthy Women Reporting Minor GI Symptoms

Evaluation of the Effect of a 28-day B.Lactis Consumption Twice Daily on Gastro-Intestinal (GI) Symptoms in Healthy Women Reporting Minor GI Symptoms. A Proof of Efficacy, Randomized, Controlled, Double-blind, Parallel Arms, Adaptive Design.

The purpose of this study is to assess the effect of a 28-day B.lactis consumption twice daily on Gastro-Intestinal (GI) symptoms in healthy women reporting minor GI symptoms.

Study Overview

• Status: Completed
• Conditions: Gastro-intestinal Symptoms in Healthy Subjects
• Intervention / Treatment: Other: Freeze-dried biotic; Other: Maltodextrin

• Study Type: Interventional
• Enrollment (Actual): 486
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Dijon, France, 21000
    • CEN experimental

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Informed Consent SI01: Free-living Participant who fully understands and agree to the objectives of the study, who gave signed and dated informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• Age SI02: Women between the ages of 18 and 60 years (bounds included), at the time of signing the informed consent at the inclusion visit.
• Weight SI03: Subject with body mass index (BMI) between 18.0 and 30.0 kg/m2 (bounds included).
• Type of Participant and Disease Characteristics SI04: Subject with minor digestive symptoms as defined by composite score between 12 and 16 (bounds included) or at least one digestive symptom with a score ≥4 according to the screening questionnaire of frequency of digestive symptoms (DSFQ (R)).

SI05: Subject with mean stool frequency between 3 and 21 bowel movements per week during the past month (bounds included) according to the screening questionnaire (DSFQ (R)).

• Sex SI06: Women of childbearing potential must be using a medically approved method of contraception (Oral birth control pills, Intra-uterine device (IUD) or Double barrier methods (such as condoms and spermicide)) OR women must be postmenopausal for at least 12 months prior to study entry OR women surgically sterile (i.e. hysterectomy, bilateral oophorectomy or bilateral tubal ligation).
• Other SI07: Subject willing to strictly follow dietary instructions (unauthorized products) for the entire duration of the study.

SI08: Subject must have access to adequate space to store the investigational products (storage at 4°C) and the stools samples (storage in freezer) according to the labels' storage recommendations.

SI09: Subject able to communicate well with the investigator and to comply with the requirements for the entire study.

SI10: Subject covered by health insurance or covered by a similar system. SI11: Subject agrees to be registered in the National biomedical research file for volunteers.

SI12: Subject willing to complete ePRO through a smartphone compatible with playstore or apple store and having access to internet.

Exclusion Criteria:

- Medical Conditions and History SE01: Pregnant women based on pregnancy test or planning to become pregnant during the study's participation or lactating women.

SE02: Subject with disorder of gut brain interactions according to ROME IV criteria (Functional Bowel Disorders/FBD module, Functional Dyspepsia/FD module).

SE03: Subject with gastrointestinal disorders other than minor digestive symptoms as defined in SI04 according to investigator's medical assessment.

SE04: Subject who have consulted for gastrointestinal disorders within 6 months prior to the screening visit (V1).

SE05: Subject who had any dental surgery within the last 4 weeks, or who plans to have one during the study, excluding care of tooth decay.

SE06: Subject with any antecedents of digestive surgery (except for appendectomy and cholecystectomy performed more than 2 years ago).

SE07: Subject with previous history of drug or alcohol abuse 6 months prior to screening.

SE08: Subject with severe disease as assessed by the investigator (e.g inflammatory bowel disease, benign or malign tumor of intestine or colon cancer, severe heart disease, kidney disease, neurological disease or psychiatric disease, immunodeficiency disorder).

- Prior/Concomitant Therapy SE09: Subject with any intake of antibiotics or intestinal antiseptics in the previous 2 months (within 60 days) prior to the screening visit (V1).

SE10: Subject with any intake of drugs that might modify gastrointestinal function (e.g regular use of laxatives, anti-diarrhea, prokinetics, proton pump inhibitors (PPIs)) in the previous 2 weeks (within 14 days) prior to the screening visit (V1).

SE11: Subject with any intake of over-the-counter yeasts or probiotics supplements (such as pills, tablets, sachets or sticks) in the previous 2 weeks (within 14 days) prior to the screening visit (V1).

SE12: Subject who underwent a general anesthesia in the preceding 4 weeks. SE13: Subject with known allergy to study products component (maltodextrin for example).

SE14: Subject with any current use of any medication with potential central nervous system effects as judged by the investigator (including but not limited to opiate pain medication).

- Prior/Concurrent Clinical Study Experience SE15: Subject who has planned to participate in another investigational study during the period of this study OR subject involved in any other clinical study within the preceding month except for non-investigational procedures (e.g: CT scan, endoscopy capsule) OR subject in the exclusion period after participation in another clinical study.

Diet SE16: Change of dietary habits within the 4 weeks preceding the V1 (for instance start of a diet rich in fiber) or planned change (for example to start a new diet during the study's participation).

- Other Exclusions SE17: Vulnerable subjects defined as individuals whose willingness to volunteer in the clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate (examples are members of a group with a hierarchical structure linked to the Investigator or to the Sponsor, such as medical, pharmacy, dental and nursing students, subordinate hospital and laboratory personnel, employees of the Investigator or of the Sponsor, members of the armed forces, and persons kept in detention).

SE18: Subject under guardianship or curatorship. SE19: Subject expected to be living in the same home as a subject currently participating to the present study (or willing to) and to concomitantly receive some study products.

SE20: Subject planning to start or quit smoking during the study's participation.

SE21: Subject in a situation, which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject.

SE22: Subject not able to understand and/or to answer to the questions. SE23: Athletes as defined as routinely performing strenuous daily exercise for more than 1.5 hours at a time.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Arm 1, Test: freeze-dried B. lactis	Other: Freeze-dried biotic; 2 sticks of 3g consumed daily for 28 days
Other: Arm 2, Control: freeze-dried maltodextrin	Other: Maltodextrin; 2 sticks of 3g consumed daily for 28 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Comparison between groups of scores of Digestive Symptoms Frequency Questionnaire (DSFQ) during 28 days of investigational product consumption (the higher the score, the more severe are the symptoms, min:0, no symptom, max:16).	From Baseline to Visit 4 (28 days).

Secondary Outcome Measures

Outcome Measure	Time Frame
Comparison between groups of scores of Digestive Symptoms Frequency Questionnaire (DSFQ) during 28 days of investigational product consumption (the higher the score, the more severe are the symptoms, min:0, no symptom, max:16).	From Baseline to each weekly evaluation visits (Week1 to Week 4) (4 weeks from baseline).
Comparison between groups of scores of Intestinal Gas Questionnaire (IGQ) during 28 days of investigational product consumption (the higher the score, the more severe are the symptoms, min:0).	From Week0 (V2) to each weekly evaluation visits (Week1 to Week4).
Comparison between groups of scores of Profile of Mood States questionnaire Short Form (POMS-SF) during 28 days of investigational product consumption (a scoring guide needs to be follow to interpreted).	From Week0 (V2) to Week2 (V3) and Week4 (V4).
Comparison between and within groups of total and living bacteria cells counts of B.lactis (method PMA-PCR) during 28 days of investigational product consumption and after 1 week following product consumption cessation.	Between Week0 (V2), Week2 (V3), Week4 (V4) and Week5 (V5).

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison between and within groups of Food Frequency Questionnaire (FFQ) during 28 days of investigational product consumption (an algorithm will be used to assess quantity and quality of nutriment intake, developed by MS Nutrition company).		Between Week0 (V2) and Week4 (V4).
Comparison between groups of scores of Digestive Symptoms Frequency Questionnaire (DSFQ) during 28 days of investigational product consumption (the higher the score, the more severe are the symptoms, min:0, no symptom, max:16).	Scoring comparison (no unit)	From Week0 (V2) to each weekly evaluation visits (Week1 to Week4).
Comparison between groups of scores of Intestinal Gas Questionnaire (IGQ) during 28 days of investigational product consumption (the higher the score, the more severe are the symptoms, min:0).	Scoring comparison (no unit)	From Week0 (V2) to each weekly evaluation visits (Week1 to Week4).
Exploratory endpoint: Comparison within and between groups of microbiota alpha diversity (metagenomic and metatranscriptomic to be defined) during 28 days study product consumption and after 1 week following product consumption cessation.		From Week0 (V2) to Week2 (V3), Week4 (V4), and Week5 (V5).
Exploratory endpoint: Comparison within and between groups of microbiota beta diversity (metagenomic and metatranscriptomic to be defined) during 28 days of study product consumption and after 1 week following product consumption cessation.		From Week0 (V2) to Week2 (V3), Week4 (V4), and Week5 (V5).
Exploratory endpoint: Comparison within and between groups of microbiota taxonomy (metagenomic and metatranscriptomic to be defined) during 28 days of study product consumption and after 1 week following product consumption cessation.		From Week0 (V2) to Week2 (V3), Week4 (V4), and Week5 (V5).
Exploratory endpoint: Comparison within and between groups of microbiota beta activity (metagenomic, analysis methods to be defined) during 28 days of investigational product consumption and after 1 week following product consumption cessation.		From Week0 (V2) to Week2 (V3), Week4 (V4), and Week5 (V5).
Exploratory endpoint: Comparison within and between groups of microbiota beta activity (metatranscriptomic, analysis methods to be defined) during 28 days of investigational product consumption and after 1 week following product consumption cessation.		From Week0 (V2) to Week2 (V3), Week4 (V4), and Week5 (V5).
Exploratory endpoint: Comparison within B.lactis group of microbiota alpha and beta-diversity (bioinformatic) during and following cessation of product consumption.		From Week0 (V2) to Week2 (V3), Week4 (V4), and Week5 (V5).
Exploratory endpoint: Comparison within B.lactis group of microbiota abundance (composition) (bioinformatic) during and following cessation of product consumption.		From Week0 (V2) to Week2 (V3), Week4 (V4), and Week5 (V5).
Exploratory endpoint: Comparison within B.lactis group of microbiota abundance (function, no specific method of measurement has been defined yet) during and following cessation of product consumption.		From Week0 (V2) to Week2 (V3), Week4 (V4), and Week5 (V5).
Exploratory endpoint: Comparison within B.lactis group of total and living bacteria cells counts of B.lactis (method PMA-PCR) during and following cessation of product consumption.		From Week0 (V2) to Week2 (V3), Week4 (V4), and Week5 (V5).

Collaborators and Investigators

• Sponsor: Danone Research
• Collaborators: Euraxi Pharma
• Investigators: Study Chair: Rim HASSOUNA, PhD, Danone Research, Palaiseau, France

Study record dates

Study Major Dates

• Study Start (Actual): May 24, 2022
• Primary Completion (Actual): December 15, 2023
• Study Completion (Actual): April 18, 2024

Study Registration Dates

• First Submitted: May 12, 2022
• First Submitted That Met QC Criteria: June 9, 2022
• First Posted (Actual): June 13, 2022

Study Record Updates

• Last Update Posted (Actual): August 9, 2024
• Last Update Submitted That Met QC Criteria: August 7, 2024
• Last Verified: August 1, 2024

More Information

Terms related to this study

• Keywords: Randomized controlled trial; Healthy women; Gastro intestinal symptoms; Freeze-dried probiotic product
• Other Study ID Numbers: NU390

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No